John Baker says the founding team opened a £1 profiling shop on King's College campus in 2021. They used it to build the first high-resolution dataset of 1,000 immune systems, now shown on the office wall as the healthy-immune reference. That scrappy sampling gave IMU a population baseline before UK Biobank.
In a UK-wide immuno-oncology program, John Baker says IMU's pre-treatment immune profile separates patients likely to respond to anti-PD-L1 or checkpoint inhibitor combinations. It also flags before the first dose who may suffer severe immune-mediated adverse events, so clinicians can monitor and manage those patients more actively. Response rates are only 30-40%.
John Baker says live Biobank blood cells are destroyed once a tube is taken out and run on IMU's platform, and many samples are aged. To maximize each one, IMU extracts hundreds of millions of proteomic immunology measurements plus high-resolution single-cell gene expression, then uses neural networks to map those datasets together.
John Baker says the immune system shifts with breakfast, exercise and circadian rhythms, yet some anchoring features stay consistent for years or decades. IMU wants to separate those stable anchors from the modifiable parts so it can understand disease progression and treatment effects across a population over time.
John Baker says IMU has about 35 people in Canary Wharf, the vast majority of its global team. He claims the wet-lab and in-silico platform is efficient enough for that team to handle the full Biobank volume, which runs from a few hundred samples now to tens or hundreds of thousands.
